What recovery looks like on injection day

Most patients leave the clinic walking under their own power within minutes of receiving a ChondroFiller injection into the hip — there is no anaesthetic, no operating theatre, and no surgical recovery period to navigate. Because the treatment is delivered through a precisely targeted, ultrasound-guided needle, it sits in a very different category from the surgical cartilage repair procedures patients sometimes read about online.

For the first 24–48 hours, reduced activity is sensible. The collagen scaffold needs that window to gel securely within the hip joint before normal loading resumes. This is not strict non-weight-bearing on crutches; it is simply a quieter couple of days — avoiding prolonged walking, heavy lifting, or anything that creates sudden impact through the hip.

A brace is not required for the majority of patients on this pathway. After the initial rest period, normal daily activity can return gradually, guided by comfort rather than a rigid timetable. The clinical team will advise on pacing based on individual hip condition and how the joint responds.

Why the hip scaffold takes time to do its job

Once the collagen scaffold has gelled in place, the real work falls to the body. ChondroFiller's Type I collagen matrix acts as a structural scaffold within the hip joint, creating a micro-environment that draws the patient's own progenitor cells into the defect site. Those cells — already circulating in the synovial fluid and surrounding tissue — migrate into the gel and begin laying down cartilage-like tissue. No donor cells are introduced, which is precisely why delivery can be outpatient and image-guided rather than theatre-based.

This biological process — matrix-induced chondrogenesis — unfolds gradually. Over the first weeks and months, immature tissue starts to fill the defect; by 12–24 months, the scaffold itself is progressively resorbed and replaced by the patient's own repair tissue. The one-to-two-year window is not a recovery period in the conventional sense; most patients feel meaningfully better well before that. It is, rather, the timeframe across which cartilage maturation completes in the background.

The reason activity guidance matters during this period comes down to mechanics. Excessive shear forces — the rotational and sliding loads that pass through a weight-bearing hip joint during high-impact movement — can disturb the scaffold before the new tissue has gained sufficient structure to resist them. Graduating the return to loading is not an arbitrary restriction; it maps directly onto the biology happening inside the joint.

Weight-bearing and movement in the first six weeks

The six weeks following a ChondroFiller injection into the hip divide naturally into two distinct modes: an initial rest window and a longer period of managed, low-impact activity.

After the first 24–48 hours of reduced activity covered in section one, full weight-bearing is permitted. Unlike the arthroscopic surgical pathway — where strict non-weight-bearing for up to three weeks is standard — the injection route does not require crutches for most patients. Short, gentle walks are encouraged from this point: they support circulation around the hip joint and assist the early scaffold-integration process without generating the shear forces that could disturb consolidating tissue.

For the remainder of the first six weeks, the practical rule is to stay low-impact. Running, jumping, sudden direction changes, and heavy lifting should be avoided while the scaffold is consolidating. Swimming and stationary cycling — which feature in later-stage recovery after surgical procedures — are not the target here; straightforward daily walking and gentle unloaded movement are what this phase calls for.

Patients can expect some mild aching around the hip and occasional warmth at the injection site in the early days; both are normal responses. What warrants a call to the clinic team is different in character: sharp or worsening pain that does not settle, marked swelling, or any new symptom that feels out of proportion to the procedure. The clinical team at Lincolnshire Hip can advise whether what a patient is experiencing falls within the expected range.

Rebuilding hip strength from weeks six to twelve

Reaching week six marks a genuine shift in emphasis. Protecting the scaffold from overload remains important, but the priority now becomes rebuilding the hip's own muscular support — because long-term joint health depends as much on the surrounding muscle environment as on the cartilage itself.

Supervised physiotherapy at this stage typically focuses on the hip abductors, extensors, and deep stabilisers: the muscles that control the pelvis during single-leg loading and reduce the forces transmitted through the cartilage defect site. Proprioceptive exercises — balance and joint-position work — are introduced alongside progressive resistance, gradually teaching the hip to handle functional demands again.

Iliopsoas engagement and resisted hip flexion are generally reintroduced with care. Loading the hip flexor too early can generate shear forces at the anterior joint line; when and how these exercises progress depends on the defect location and individual hip function, and is a decision for the treating physiotherapist rather than a fixed calendar point.

Structured physiotherapy, rather than unsupervised gym training, matters here precisely because the strengthening stimulus and the load tolerance of the healing scaffold need to be matched. The published hip ChondroFiller cohort data — including the Mazek 2021 study of 26 FAI patients — report a mean improvement of approximately 33 points on the modified Hip Harris Score at 3–5 years post-procedure. That figure reflects the cohort as a whole over the full maturation period; it is not a target for week twelve, and individual results will differ based on defect size, baseline hip function, and the quality of rehabilitation.

Return to sport and higher-impact activity milestones

The milestone ladder for returning to sport follows a broadly consistent pattern across expert-consensus protocols and the available hip-specific literature — including the Mazek 2021 cohort of 26 FAI patients, the largest published hip dataset for this procedure. It is worth noting that formal randomised controlled trials comparing rehabilitation timelines specifically for ChondroFiller in the hip joint have not yet been conducted, which means these timeframes carry some inherent flexibility rather than the precision of head-to-head trial data.

Swimming and stationary cycling are typically introduced at around four months. Both sustain aerobic fitness and hip muscle endurance while keeping ground-strike shear forces low — a practical fit with the scaffold's ongoing maturation at that stage.

Running and higher-impact activities are generally withheld until at least twelve months post-injection. For patients whose hip also required concurrent treatment — labral repair, for example — that window is usually extended further. The twelve-month point is not an automatic clearance; it is the earliest realistic moment to begin the return-to-running conversation with the clinical team, supported by clinical review and, where appropriate, imaging to confirm tissue maturity.

Contact sport and heavy manual work require specific clearance. A fixed calendar date does not drive these decisions; functional testing, loading-related pain response, and clinical assessment together determine readiness.

Throughout every phase, comfort-led progression remains the practical guide. Persistent hip pain during or after activity is a signal to reduce load, not override it.

How your individual hip shapes the recovery timeline

Recovery timelines for a ChondroFiller hip injection are not uniform — several clinical factors pull the timetable in different directions, and understanding them helps patients set realistic expectations before treatment begins.

Defect size is the most straightforward modifier. ChondroFiller is indicated for focal cartilage defects, typically up to 3 cm² and extendable to 6 cm²; where cartilage loss is larger or more diffuse, the scaffold is unlikely to be the appropriate pathway, and the clinical conversation shifts toward different options entirely.

Tönnis grade — a measure of underlying hip osteoarthritis severity on imaging — matters considerably. The Mazek 2021 cohort of 26 FAI patients demonstrated that individuals with Tönnis grade 2–3 pre-existing osteoarthritis fared poorly, whereas those with lower-grade disease achieved good-to-excellent results at 3–5 years in 17 of 21 evaluable cases. A higher Tönnis grade may indicate that cartilage regeneration is no longer a realistic goal for that hip.

Concurrent hip diagnoses also shape recovery. A patient who has had labral pathology addressed alongside the cartilage injection faces additional tissue healing constraints that modify how quickly loading and strengthening can progress.

These variables — defect dimensions, joint grade, and the full picture of hip pathology — are why personalised guidance from an experienced hip clinician is essential rather than optional. Professor Paul Lee at Lincolnshire Hip bases recovery planning on each patient's hip imaging and activity profile. Lincolnshire Hip accepts patients without a GP referral.

1. [1] Hip Chondral Defects: Arthroscopic Treatment With the Needle and Curette Technique and ChondroFiller. (2021). https://doi.org/10.1016/j.eats.2021.03.011 https://doi.org/10.1016/j.eats.2021.03.011
2. [2] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002